SCHEMBL829172

SCHEMBL829172

COC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCO

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4104455 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL64957 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL829630 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL9720673 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL829291 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL830178 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL829553 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL679835 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL98075 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL4092007 1.00 MEN1 (0.50) MEN1KMT2ATSHRMAPK1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11560475-B2 Photocurable resin composition, cured product, and laminate THREEBOND CO., LTD. (JP) 2023-01-24 US claimed
EP-2121025-A2 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT Hananja Ehf (IS) 2009-11-25 EP claimed
US-20090227568-A1 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT HANANJA EHF (IS) 2009-09-10 US claimed
US-20080275030-A1 alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") 2008-11-06 US claimed
WO-2008089426-A2 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT HANANJA EHF (IS) 2008-07-24 WO claimed
US-20260115361-A1 METHOD FOR PRODUCING ANTITHROMBOGENIC MATERIAL TOYOBO CO.,LTD. (JP) 2026-04-30 US disclosed
EP-4714983-A1 PHOTOCURABLE RESIN COMPOSITION AND CURED OBJECT FORMED THEREFROM ThreeBond Co., Ltd. (JP) 2026-03-25 EP disclosed
EP-4691508-A1 METHOD FOR MANUFACTURING ANTITHROMBOTIC MEDICAL DEVICE Toyobo Co., Ltd. (JP) 2026-02-11 EP disclosed
US-12539313-B2 Microbial removal CAPRETTO EHF. (IS) 2026-02-03 US disclosed
EP-3934753-B1 MICROBIAL REMOVAL CAPRETTO EHF (IS) 2025-11-05 EP disclosed
US-20250329859-A1 APPLICATION SYSTEM AESC JAPAN LTD (JP) 2025-10-23 US disclosed
EP-4635636-A1 APPLICATION SYSTEM AESC Japan Ltd. (JP) 2025-10-22 EP disclosed
US-20110300091-A1 TRANSLUCENT DEODORANT STICKS CONTAINING SOLUBILIZED 3,4,4'-TRICHLOROCARBANILIDE THE DIAL CORPORATION (US) 2011-12-08 US disclosed
US-20100135852-A1 OXYGENATOR OF A HOLLOW FIBER MEMBRANE TYPE TOYO BOSEKI KABUSHIKI KAISHA (JP) 2010-06-03 US disclosed
EP-2156856-A1 HOLLOW FIBER MEMBRANE-TYPE ARTIFICIAL LUNG Toyo Boseki Kabushiki Kaisha (JP) 2010-02-24 EP disclosed
EP-2121025-A2 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT Hananja Ehf (IS) 2009-11-25 EP disclosed
EP-2100627-A1 (METH)ACRYLATE COPOLYMER, PROCESS FOR PRODUCING THE SAME AND MEDICAL DEVICE Toyo Boseki Kabushiki Kaisha (JP) 2009-09-16 EP disclosed
US-20090227568-A1 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT HANANJA EHF (IS) 2009-09-10 US disclosed
US-20080275030-A1 alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") 2008-11-06 US disclosed
WO-2008089426-A2 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT HANANJA EHF (IS) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115361-A1 METHOD FOR PRODUCING ANTITHROMBOGENIC MATERIAL SERPINC1, FGB, ADAMTS13 MEN1 490/4885KMT2A 1470/4885TSHR 149/4885
US-20090227568-A1 METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT TMEM205, NUP205, PIGS MEN1 832/4885KMT2A 3911/4885TSHR 2833/4885
US-12539313-B2 Microbial removal CUTA, MIF, PCNA MEN1 782/4885KMT2A 2838/4885TSHR 811/4885
US-20080275030-A1 alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug OPRD1, DRD2, DRD1 MEN1 3906/4885KMT2A 2581/4885TSHR 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.